|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.04.25 - 15:03
|
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) (GlobeNewswire EN)
|
|
|
Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) and insights into APDS and additional primary immunodeficiencies (PIDs) with immune dysregulation....
|
|
|
24.04.25 - 13:12
|
NICE issues final guidance endorsing Pharming′s APDS therapy (PBR)
|
|
|
This recommendation facilitates treating the activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 years and above. The oral therapy is now accessible and funded in
The post NICE issues final guidance endorsing Pharming's APDS therapy appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
17.03.25 - 12:06
|
BioStock: Last trading day for Abliva – the company leaves Nasdaq Stockholm (Cision)
|
|
|
Today marks the end of an era for Abliva on Nasdaq Stockholm. Based on an application from the company's board, the stock is being delisted, and today, March 17, 2025, is the final trading day for the company's shares. This is a natural consequence of the takeover bid presented by Pharming Technologies late last year and the subsequent process that has led to Pharming taking full control over the company.
Read the full article at biostock.se (https://www.biostock.se/en/):
https://www.biostock.se/en/2025/03/last-trading-day-for-abliva-the-company-leaves-nasdaq-stockholm/
This is a press...
|
|
|
|
|
|
|
|
|
06.03.25 - 20:12
|
Pharming Technologies B.V. announces the final outcome of the recommended cash offer to the shareholders of Abliva AB (publ) (Cision)
|
|
|
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this press...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
